Cargando…
Primary progression during frontline CIT associates with decreased efficacy of subsequent CD19 CAR T-cell therapy in LBCL
| Autores principales: | , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
American Society of Hematology
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9278282/ https://www.ncbi.nlm.nih.gov/pubmed/35816359 http://dx.doi.org/10.1182/bloodadvances.2022007006 |
| _version_ | 1784746154112581632 |
|---|---|
| author | Perez, Ariel Johnson, Grace Patel, Kedar Arciola, Brian Wood, Anthony Bachmeier, Christina A. Chavez, Julio C. Shah, Bijal D. Khimani, Farhad Nishihori, Taiga Lazaryan, Aleksandr Davila, Marco L. Mhaskar, Rahul Locke, Frederick L. Gaballa, Sameh Jain, Michael D. |
| author_facet | Perez, Ariel Johnson, Grace Patel, Kedar Arciola, Brian Wood, Anthony Bachmeier, Christina A. Chavez, Julio C. Shah, Bijal D. Khimani, Farhad Nishihori, Taiga Lazaryan, Aleksandr Davila, Marco L. Mhaskar, Rahul Locke, Frederick L. Gaballa, Sameh Jain, Michael D. |
| author_sort | Perez, Ariel |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9278282 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | American Society of Hematology |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-92782822022-08-01 Primary progression during frontline CIT associates with decreased efficacy of subsequent CD19 CAR T-cell therapy in LBCL Perez, Ariel Johnson, Grace Patel, Kedar Arciola, Brian Wood, Anthony Bachmeier, Christina A. Chavez, Julio C. Shah, Bijal D. Khimani, Farhad Nishihori, Taiga Lazaryan, Aleksandr Davila, Marco L. Mhaskar, Rahul Locke, Frederick L. Gaballa, Sameh Jain, Michael D. Blood Adv Research Letter American Society of Hematology 2022-07-07 /pmc/articles/PMC9278282/ /pubmed/35816359 http://dx.doi.org/10.1182/bloodadvances.2022007006 Text en © 2022 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved. |
| spellingShingle | Research Letter Perez, Ariel Johnson, Grace Patel, Kedar Arciola, Brian Wood, Anthony Bachmeier, Christina A. Chavez, Julio C. Shah, Bijal D. Khimani, Farhad Nishihori, Taiga Lazaryan, Aleksandr Davila, Marco L. Mhaskar, Rahul Locke, Frederick L. Gaballa, Sameh Jain, Michael D. Primary progression during frontline CIT associates with decreased efficacy of subsequent CD19 CAR T-cell therapy in LBCL |
| title | Primary progression during frontline CIT associates with decreased efficacy of subsequent CD19 CAR T-cell therapy in LBCL |
| title_full | Primary progression during frontline CIT associates with decreased efficacy of subsequent CD19 CAR T-cell therapy in LBCL |
| title_fullStr | Primary progression during frontline CIT associates with decreased efficacy of subsequent CD19 CAR T-cell therapy in LBCL |
| title_full_unstemmed | Primary progression during frontline CIT associates with decreased efficacy of subsequent CD19 CAR T-cell therapy in LBCL |
| title_short | Primary progression during frontline CIT associates with decreased efficacy of subsequent CD19 CAR T-cell therapy in LBCL |
| title_sort | primary progression during frontline cit associates with decreased efficacy of subsequent cd19 car t-cell therapy in lbcl |
| topic | Research Letter |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9278282/ https://www.ncbi.nlm.nih.gov/pubmed/35816359 http://dx.doi.org/10.1182/bloodadvances.2022007006 |
| work_keys_str_mv | AT perezariel primaryprogressionduringfrontlinecitassociateswithdecreasedefficacyofsubsequentcd19cartcelltherapyinlbcl AT johnsongrace primaryprogressionduringfrontlinecitassociateswithdecreasedefficacyofsubsequentcd19cartcelltherapyinlbcl AT patelkedar primaryprogressionduringfrontlinecitassociateswithdecreasedefficacyofsubsequentcd19cartcelltherapyinlbcl AT arciolabrian primaryprogressionduringfrontlinecitassociateswithdecreasedefficacyofsubsequentcd19cartcelltherapyinlbcl AT woodanthony primaryprogressionduringfrontlinecitassociateswithdecreasedefficacyofsubsequentcd19cartcelltherapyinlbcl AT bachmeierchristinaa primaryprogressionduringfrontlinecitassociateswithdecreasedefficacyofsubsequentcd19cartcelltherapyinlbcl AT chavezjulioc primaryprogressionduringfrontlinecitassociateswithdecreasedefficacyofsubsequentcd19cartcelltherapyinlbcl AT shahbijald primaryprogressionduringfrontlinecitassociateswithdecreasedefficacyofsubsequentcd19cartcelltherapyinlbcl AT khimanifarhad primaryprogressionduringfrontlinecitassociateswithdecreasedefficacyofsubsequentcd19cartcelltherapyinlbcl AT nishihoritaiga primaryprogressionduringfrontlinecitassociateswithdecreasedefficacyofsubsequentcd19cartcelltherapyinlbcl AT lazaryanaleksandr primaryprogressionduringfrontlinecitassociateswithdecreasedefficacyofsubsequentcd19cartcelltherapyinlbcl AT davilamarcol primaryprogressionduringfrontlinecitassociateswithdecreasedefficacyofsubsequentcd19cartcelltherapyinlbcl AT mhaskarrahul primaryprogressionduringfrontlinecitassociateswithdecreasedefficacyofsubsequentcd19cartcelltherapyinlbcl AT lockefrederickl primaryprogressionduringfrontlinecitassociateswithdecreasedefficacyofsubsequentcd19cartcelltherapyinlbcl AT gaballasameh primaryprogressionduringfrontlinecitassociateswithdecreasedefficacyofsubsequentcd19cartcelltherapyinlbcl AT jainmichaeld primaryprogressionduringfrontlinecitassociateswithdecreasedefficacyofsubsequentcd19cartcelltherapyinlbcl |